Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 55

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 55
---
 | See                                                                                                                                                                        
 Krause et al Clin Infect Dis 2024; doi:10.1093/cid/ciae238 and https://ysph.yale.edu/news-article/antimalarial-drug-is-effective-against-tick-borne-infection-babesiosis/. |

| 14 | Marx                           
 et. al., MMWR 2021;70:612-616. |

| 15 | https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html.; 
 https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html.            |

| 16 | Dow and                                     
 Smith New Microb New Infect 2022;45:100964. |

<div align='center'>3</div>

| ● | Prevention                                                                                                                            
 of fungal pneumonias. There are up to ~ 91-92,000 new patient cases  each year in the United States for which antifungal              
 prophylaxis is recommended, including acute lymphoblastic leukemia (up to 6,540 cases) and large B-cell lymphoma (up to 18,000 cases) 
 patients receiving CAR-T therapy, solid organ transplant patients (up to 42,887 cases), allogeneic (~ 9,000 cases) and autologous     
 (~ 15,000 cases) hematopoietic stem cell transplant patients.17 Despite the availability and use of antifungal prophylaxis,           
 the risk of some patient groups contracting fungal pneumonia exceeds the risk of contracting malaria during travel to West Africa.18  
 Since it has broad spectrum antifungal effects in cell culture, and activity against Pneumocystis in animal models,                   
 Tafenoquine has the potential to be added to existing standard of care regimens for the prevention of fungal pneumonias.19            |

Viral Diseases Celgosivir, a potential clinical candidate of 60P’s, has activity in a number of animal models of important viral diseases such as Dengue and RSV. According to the European CDC, Dengue is associated with at least 4.1 million cases globally. 20And, according to the U.S. CDC, RSV is responsible for up to 240,000 hospitalizations in children less than five years of age and adults greater than 65 years of age in the United States each year. 21As outlined in the “ Strategy” section below, we expect to evaluate Celgos